EQS-News: ckert & Ziegler: Annual General Meeting Approves Dividend of EUR 0.50 per Share. Reorganization of the Executive Board, Supervisory Board and Group Executive Committee.
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG
/ Key word(s): AGM/EGM/Personnel
ckert & Ziegler: Annual General Meeting Approves Dividend of EUR 0.50 per Share. Reorganization of the Executive Board, Supervisory Board and Group Executive Committee.
07.06.2023 / 17:18 CET/CEST
The issuer is solely responsible for the content of this announcement.
Berlin, 7 June 2023. At today's Annual General Meeting of Eckert & Ziegler AG, the shareholders approved the proposal of the Executive Board and Supervisory Board to distribute a dividend of 0.50 EUR per dividend-bearing share. All items on the agenda were accepted by the shareholders. A total of 57.75% of the share capital of Eckert & Ziegler AG was represented at the Annual General Meeting.
At the end of the Annual General Meeting, the former Chairman of the Executive Board and founder Dr. Andreas Eckert (63) moved to the Supervisory Board. As planned, Dr. Harald Hasselmann (56), member of the Executive Board and responsible for the Medical segment, thus takes over as Chairman of the Executive Board. The long-standing Chairman of the Supervisory Board, Prof. Dr. Wolfgang Maennig, left the Supervisory Board at the end of the Annual General Meeting.
At his own request and as part of an early retirement arrangement, Dr. Lutz Helmke is leaving the Executive Board. Newly appointed to the Executive Board and responsible for the Isotopes segment is the long-time head of this division, Frank Yeager, who is based in California. The Executive Board positions of Dr. Hakim Bouterfa and Jutta Ludwig remain unaffected by the changes. A new member of the Executive Committee will be Ana Ramirez, for many years General Manager within the Isotope Products segment and responsible, among others, for the Latin American business.
The documents and voting results for the Annual General Meeting are available at Eckert & Ziegler Strahlen- und Medizintechnik AG: Annual General Meeting (ezag.com)
About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse. Contributing to saving lives.
Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, [email protected], www.ezag.com
07.06.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com
|
Language: |
English |
Company: |
Eckert & Ziegler Strahlen- und Medizintechnik AG |
|
Robert-Rössle-Str.10 |
|
13125 Berlin |
|
Germany |
Phone: |
+49 30 941084-138 |
Fax: |
+49 30 941084-112 |
E-mail: |
[email protected] |
Internet: |
www.ezag.de |
ISIN: |
DE0005659700 |
WKN: |
565970 |
Indices: |
SDAX, TecDAX |
Listed: |
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: |
1652023 |
|
End of News |
EQS News Service |
1652023 07.06.2023 CET/CEST
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
Umsatzerlöse1 |
138,63 |
168,71 |
178,49 |
176,14 |
180,44 |
222,26 |
246,09 |
EBITDA1,2 |
26,62 |
32,14 |
43,13 |
44,64 |
57,04 |
55,52 |
58,83 |
EBITDA-Marge3 |
19,20 |
19,05 |
24,16 |
25,34 |
31,61 |
24,98 |
|
EBIT1,4 |
17,97 |
23,39 |
32,06 |
33,69 |
47,45 |
44,54 |
45,45 |
EBIT-Marge5 |
12,96 |
13,86 |
17,96 |
19,13 |
26,30 |
20,04 |
18,47 |
Jahresüberschuss1 |
15,12 |
16,89 |
22,48 |
23,11 |
34,66 |
29,75 |
26,77 |
Netto-Marge6 |
10,91 |
10,01 |
12,59 |
13,12 |
19,21 |
13,39 |
10,88 |
Cashflow1,7 |
26,83 |
21,21 |
40,43 |
36,79 |
33,86 |
34,30 |
47,40 |
Ergebnis je Aktie8 |
0,70 |
0,78 |
1,07 |
1,11 |
1,66 |
1,41 |
1,26 |
Dividende8 |
0,20 |
0,30 |
0,42 |
0,45 |
0,50 |
0,50 |
0,17 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: Forvis Mazars
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
Eckert & Ziegler |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
565970 |
37,780 |
Halten |
799,88 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
23,61 |
26,07 |
0,91 |
41,56 |
KBV |
KCV |
KUV |
EV/EBITDA |
3,62 |
16,88 |
3,25 |
13,08 |
Dividende '22 in € |
Dividende '23 in € |
Div.-Rendite '23 in % |
Hauptversammlung |
0,50 |
0,05 |
0,13 |
18.06.2025 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
13.05.2025 |
08.08.2025 |
14.11.2024 |
27.03.2025 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
-4,73% |
-0,76% |
2,92% |
8,60% |
|
|